SALT LAKE CITY–(BUSINESS WIRE)–Foldax® Inc. today announced that it has executed an agreement with Australia’s national science agency, CSIRO, for full ownership of a polymer technology patent family. Foldax has incorporated the polymer technology into its LifePolymer™ materials platform and has conducted […]

SALT LAKE CITY–(BUSINESS WIRE)–Foldax®, Inc. today announced that the first patients have been enrolled in the Drugs Controller General of India (DCGI)-approved clinical trial of the TRIA™ biopolymer surgical aortic heart valve. The TRIA valve reimagines the heart valve by […]

Data Presented at Cardiovascular Research Technologies (CRT) Annual Conference SALT LAKE CITY–(BUSINESS WIRE)–Foldax®, Inc. today announced the presentation of results from the first animal study of its transcatheter valve from the TRIA™ biopolymer heart valve portfolio this past weekend at […]

Publication in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions Found TRIA Aortic Heart Valve Provided Sustained Improvement in Heart Valve Function to One-Year with Good Safety Profile SALT LAKE CITY–(BUSINESS WIRE)–Foldax®, Inc. today announced publication of the […]

SALT LAKE CITY–(BUSINESS WIRE)–Foldax®, Inc. today announced that the Drugs Controller General of India (DCGI), India’s regulatory body for medical devices, has approved initiation of a clinical trial of the TRIA™ biopolymer surgical aortic heart valve. The TRIA valve reimagines […]